When Ruth Cadbury MP asked Ashley Dalton MP Parliamentary Under-Secretary (Department of Health and Social Care) about what steps the Dept for Health and Social Care was taking to improve access to treatments for Long COVID, the answer (UIN 45624) provided interesting context for the demands by ME charities, researchers and others for the government to commit to a sustained strategic investment in ME research.
Between 2019/20 and 2023/24, through the NIHR and MRC, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.
This includes funded clinical trials to test and compare different treatments such as antihistamines, anticoagulants, and anti-inflammatory medicines, as well as trials such as the approximately £1.5 million REGAIN trial funded through the NIHR. REGAIN is the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high-quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID which combine exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.
The approximately £1.9 million CLoCk study, co-funded by the NIHR and the MRC, developed an agreed definition of long COVID in children and young people as well as the associated symptoms, which will help harmonise research and improve understanding of the condition.
Funding is available and we welcome funding applications for research into long COVID in both adults and children. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
To support clinical leadership in this area, NHS England has worked in partnership with the British Society of Physical and Rehabilitation Medicine to develop a new Clinical Post-COVID Society to facilitate the ongoing sharing of best practice and to support people affected by long COVID.
It is useful to compare the Government’s answer to similar queries centred on ME/CFS, for example, the query of 16th October 2024 by The Rt Hon John McDonnell MP disclosed that –
The Department funds research in health and social care through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of long COVID and myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and are actively exploring next steps for research in these areas. This includes a roundtable I [ Andrew Gwynne MP then Parliamentary Under-Secretary (Department of Health and Social Care)] hosted on long COVID on 17 October 2024, which included discussion on how long COVID research is relevant to other post-viral syndromes and how to stimulate the research community to undertake future research.
Over the last five years, the NIHR has invested almost £2.3 million in research programme funding for ME/CFS. In addition, the NIHR and the MRC are also providing £3.2 million of co-funding towards the DecodeME study, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.
